Abstract
Levocetirizine dihydrochloride is a selective, long acting peripheral H1receptor antagonist. Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulin E (IgE) in the membrane lining the nose after allergen exposure. Thus formulating Levocetirizine into an mouth dissolving tablet dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-114 (ion exchange resin) was used to mask the taste and to formulate an mouth dissolving tablet dosage form using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, in vitro disintegration, dispersion time, hardness, friability, thickness uniformity. The tablets disintegrated in vitro within 22 to 66 seconds complete drug were released from tablet within 10 minutes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharma Professional’s Research (IJPPR)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
